Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879136 | 0.88 | ADORA2A (0.70) | ADORA2A | |
| SCHEMBL6883910 | 0.87 | ADORA2A (0.69) | ADORA2A | |
| SCHEMBL6885596 | 0.86 | ADORA2A (0.77) | ADORA2ARECQL | |
| SCHEMBL6885386 | 0.85 | ADORA2A (0.66) | ADORA2AGRM5 | |
| SCHEMBL6885255 | 0.84 | ADORA2A (0.70) | ADORA2ARECQLCA12CA1CA2 | |
| SCHEMBL6885158 | 0.83 | ADORA2A (0.82) | ADORA2A | |
| SCHEMBL6882517 | 0.82 | ADORA2A (0.63) | ADORA2A | |
| SCHEMBL6885370 | 0.82 | ADORA2A (0.78) | ADORA2ARECQL | |
| SCHEMBL6878009 | 0.81 | ADORA2A (0.63) | ADORA2ARECQLCA12CA1CA2 | |
| SCHEMBL6878200 | 0.81 | ADORA2A (0.77) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-12-01 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889082-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-12-01 | — | — | US | disclosed |
| US-9254293-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-01-27 | — | — | US | disclosed |
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-01-27 | — | — | US | disclosed |
| US-6689790-B2 | 8-AMINO-6-AMIDO-SUBSTITUTED-(1,2,4)TRIAZOLO(1,5-A)PYRIDINES; ADENOSINE RECEPTOR MODULATERS | HOFFMANN-LA ROCHE INC. | 2004-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021599-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | ADORA2A 1163/4885RECQL 3256/4885CA12 2197/4885 |
| US-20160346186-A1 | METHODS AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER, AND BPH | AR, BPHL, PTGS2 | ADORA2A 1163/4885RECQL 3256/4885CA12 2197/4885 |
| US-10849841-B2 | Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH | AR, BPHL, PTGS2 | ADORA2A 1163/4885RECQL 3256/4885CA12 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.